evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from mri contrast agents several mri contrast agent clinical formulations are now known to leave deposits of the heavy metal gadolinium in the brain bones and other organs of patients this persistent biological accumulation of gadolinium has been recently recognized as a deleterious outcome in patients administered gdbased contrast agents gbcas for mri prompting the european medicines agency to recommend discontinuing the use of over half of the gbcas currently approved for clinical applications to address this problem we find that the orallyavailable metal decorporation agent 343li12hopo demonstrates superior efficacy at chelating and removing gd from the body compared to diethylenetriaminepentaacetic acid a ligand commonly used in the united states in the gbca gadopentetate magnevist using the radiotracer 153gd to obtain precise biodistribution data the results herein supported by speciation simulations suggest that the prophylactic or posthoc therapeutic use of 343li12hopo may provide a means to mitigate gd retention in patients requiring contrastenhanced mri